Danaher (NYSE:DHR) had its price target boosted by Stifel Nicolaus from $110.00 to $115.00 in a research report issued on Wednesday. The brokerage currently has a “buy” rating on the conglomerate’s stock. Stifel Nicolaus’ price target would suggest a potential upside of 13.55% from the company’s current price.
DHR has been the subject of a number of other research reports. Cowen restated a “buy” rating and set a $90.00 price objective on shares of Danaher in a research report on Wednesday, October 4th. Morgan Stanley restated an “overweight” rating and set a $95.00 price objective (up previously from $86.00) on shares of Danaher in a research report on Friday, October 6th. Credit Suisse Group restated an “outperform” rating and set a $105.00 price objective (up previously from $99.00) on shares of Danaher in a research report on Wednesday. Zacks Investment Research raised Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price on the stock in a research note on Thursday, October 5th. Finally, Evercore ISI started coverage on Danaher in a research note on Wednesday, January 3rd. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $98.74.
Danaher (NYSE DHR) traded down $0.32 during trading hours on Wednesday, reaching $101.28. The company had a trading volume of 3,261,268 shares, compared to its average volume of 2,380,000. Danaher has a twelve month low of $78.97 and a twelve month high of $104.82. The firm has a market cap of $70,450.00, a price-to-earnings ratio of 28.94, a P/E/G ratio of 2.25 and a beta of 1.03. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42.
In other Danaher news, SVP Daniel Raskas sold 37,870 shares of Danaher stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $93.33, for a total transaction of $3,534,407.10. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 12.20% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. National Asset Management Inc. raised its stake in shares of Danaher by 0.4% in the 2nd quarter. National Asset Management Inc. now owns 3,767 shares of the conglomerate’s stock worth $318,000 after buying an additional 14 shares in the last quarter. Brighton Jones LLC raised its stake in shares of Danaher by 0.4% in the 2nd quarter. Brighton Jones LLC now owns 5,159 shares of the conglomerate’s stock worth $435,000 after buying an additional 21 shares in the last quarter. Simmons Bank raised its stake in shares of Danaher by 0.4% in the 2nd quarter. Simmons Bank now owns 7,160 shares of the conglomerate’s stock worth $604,000 after buying an additional 26 shares in the last quarter. Horizon Investments LLC raised its stake in shares of Danaher by 0.4% in the 2nd quarter. Horizon Investments LLC now owns 7,828 shares of the conglomerate’s stock worth $648,000 after buying an additional 28 shares in the last quarter. Finally, Newman Dignan & Sheerar Inc. raised its stake in shares of Danaher by 0.5% in the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 7,469 shares of the conglomerate’s stock worth $630,000 after buying an additional 35 shares in the last quarter. 76.16% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Danaher (DHR) Given New $115.00 Price Target at Stifel Nicolaus” was originally posted by American Market News and is the sole property of of American Market News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/31/danaher-dhr-given-new-115-00-price-target-at-stifel-nicolaus.html.
About Danaher
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
